{"id":63314,"date":"2026-04-16T17:42:17","date_gmt":"2026-04-16T09:42:17","guid":{"rendered":"https:\/\/flcube.com\/?p=63314"},"modified":"2026-04-16T17:42:18","modified_gmt":"2026-04-16T09:42:18","slug":"shionogi-launches-corporate-venture-capital-initiative-with-strategic-investment-in-ophthalmology-startup-restore-vision","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63314","title":{"rendered":"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision"},"content":{"rendered":"\n<p><strong>Shionogi &amp; Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4507:TYO\">TYO: 4507<\/a>) has announced the completion of its first corporate venture capital (CVC) investment, acquiring an equity stake in <strong>Restore Vision Inc.<\/strong>, a Tokyo-based startup focused on developing innovative ophthalmology technologies. This transaction marks the inaugural deal under Shionogi&#8217;s CVC program, established in April 2025 to identify and cultivate next-generation growth opportunities aligned with the company&#8217;s long-term strategic vision.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-corporate-venture-capital-framework\">Corporate Venture Capital Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>CVC Launch Date<\/strong><\/td><td>April 2025<\/td><\/tr><tr><td><strong>First Investment<\/strong><\/td><td>Restore Vision Inc. (ophthalmology technology startup)<\/td><\/tr><tr><td><strong>Initial Annual Budget<\/strong><\/td><td>USD 14 million total allocation<\/td><\/tr><tr><td><strong>FY2025 Allocation<\/strong><\/td><td>USD 7 million deployed<\/td><\/tr><tr><td><strong>Investment Stages<\/strong><\/td><td>Seed, early-stage, and mid-stage companies<\/td><\/tr><tr><td><strong>Geographic Focus<\/strong><\/td><td>Japan, United States, Europe, and Asia<\/td><\/tr><tr><td><strong>Strategic Alignment<\/strong><\/td><td>&#8220;Shionogi 2030\u20132040 Vision&#8221; for breakthrough innovations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-company-profile-restore-vision-inc\">Target Company Profile \u2013 Restore Vision Inc.<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Headquarters:<\/strong> Tokyo, Japan<\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> Ophthalmology and vision restoration technologies<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> Innovative approaches to address unmet needs in eye diseases<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Early-stage company with proprietary technology platform<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Global ophthalmology market valued at USD 38 billion in 2025, growing at 6.2% CAGR driven by aging populations and technological advances<\/li>\n<\/ul>\n\n\n\n<p>Restore Vision represents an ideal strategic fit for Shionogi&#8217;s CVC initiative, combining cutting-edge ophthalmology innovation with proximity to Shionogi&#8217;s Japanese operational base and potential for global commercialization.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-shionogi-amp-co-ltd\">For Shionogi &amp; Co., Ltd.<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vision Alignment:<\/strong> Directly supports the &#8220;Shionogi 2030\u20132040 Vision&#8221; by accessing breakthrough technologies in emerging therapeutic areas<\/li>\n\n\n\n<li><strong>Portfolio Diversification:<\/strong> Expands beyond traditional anti-infectives and CNS franchises into high-growth ophthalmology segment<\/li>\n\n\n\n<li><strong>Innovation Pipeline:<\/strong> Creates optionality for future licensing, partnerships, or acquisitions as portfolio companies mature<\/li>\n\n\n\n<li><strong>Ecosystem Development:<\/strong> Establishes presence in Japan&#8217;s growing healthtech startup ecosystem while maintaining global investment reach<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cvc-program-objectives\">CVC Program Objectives<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Strategic Breakthroughs:<\/strong> Identify technologies that can deliver transformative impact rather than incremental improvements<\/li>\n\n\n\n<li><strong>Emerging Markets Access:<\/strong> Gain early exposure to disruptive innovations in cutting-edge technology fields<\/li>\n\n\n\n<li><strong>Risk-Adjusted Returns:<\/strong> Balance strategic value creation with financial return expectations typical of venture capital investments<\/li>\n\n\n\n<li><strong>Talent Acquisition:<\/strong> Potential pathway to attract entrepreneurial talent and innovative thinking into Shionogi&#8217;s core operations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-industry-implications\">Market Context &amp; Industry Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Japanese Pharma CVC Trend:<\/strong> Increasing adoption of corporate venture capital models among Japanese pharmaceutical companies seeking external innovation<\/li>\n\n\n\n<li><strong>Ophthalmology Innovation:<\/strong> Rapid technological advances in gene therapy, sustained drug delivery, and digital diagnostics creating new treatment paradigms<\/li>\n\n\n\n<li><strong>Asia Healthtech Ecosystem:<\/strong> Growing maturity of startup ecosystems across Japan, China, and Southeast Asia attracting global pharmaceutical investment<\/li>\n\n\n\n<li><strong>Investment Climate:<\/strong> Favorable conditions for early-stage healthcare investments with strong government support for life sciences innovation in Japan<\/li>\n<\/ul>\n\n\n\n<p>&#8220;This inaugural CVC investment in Restore Vision exemplifies our commitment to identifying and nurturing breakthrough innovations that align with our long-term vision,&#8221; said Isao Teshirogi, President and CEO of Shionogi. &#8220;By establishing strategic partnerships with promising startups, we can accelerate our transformation into a globally competitive healthcare innovator.&#8221;<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding investment strategy, portfolio development, and strategic objectives. Actual results may differ due to risks including investment performance, market conditions, regulatory changes, and competitive dynamics in the global pharmaceutical and biotechnology sectors.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shionogi &amp; Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63316,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[20,44,4697,423,2673],"class_list":["post-63314","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-finance","tag-ophthalmology","tag-restore-vision","tag-shionogi","tag-tyo-4507"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture capital (CVC) investment, acquiring an equity stake in Restore Vision Inc., a Tokyo-based startup focused on developing innovative ophthalmology technologies. This transaction marks the inaugural deal under Shionogi&#039;s CVC program, established in April 2025 to identify and cultivate next-generation growth opportunities aligned with the company&#039;s long-term strategic vision.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63314\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision\" \/>\n<meta property=\"og:description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture capital (CVC) investment, acquiring an equity stake in Restore Vision Inc., a Tokyo-based startup focused on developing innovative ophthalmology technologies. This transaction marks the inaugural deal under Shionogi&#039;s CVC program, established in April 2025 to identify and cultivate next-generation growth opportunities aligned with the company&#039;s long-term strategic vision.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63314\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T09:42:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T09:42:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision\",\"datePublished\":\"2026-04-16T09:42:17+00:00\",\"dateModified\":\"2026-04-16T09:42:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314\"},\"wordCount\":506,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1603.webp\",\"keywords\":[\"Finance\",\"Ophthalmology\",\"Restore Vision\",\"Shionogi\",\"TYO: 4507\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63314#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63314\",\"name\":\"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1603.webp\",\"datePublished\":\"2026-04-16T09:42:17+00:00\",\"dateModified\":\"2026-04-16T09:42:18+00:00\",\"description\":\"Shionogi & Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture capital (CVC) investment, acquiring an equity stake in Restore Vision Inc., a Tokyo-based startup focused on developing innovative ophthalmology technologies. This transaction marks the inaugural deal under Shionogi's CVC program, established in April 2025 to identify and cultivate next-generation growth opportunities aligned with the company's long-term strategic vision.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63314\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63314#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision - Insight, China&#039;s Pharmaceutical Industry","description":"Shionogi & Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture capital (CVC) investment, acquiring an equity stake in Restore Vision Inc., a Tokyo-based startup focused on developing innovative ophthalmology technologies. This transaction marks the inaugural deal under Shionogi's CVC program, established in April 2025 to identify and cultivate next-generation growth opportunities aligned with the company's long-term strategic vision.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63314","og_locale":"en_US","og_type":"article","og_title":"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision","og_description":"Shionogi & Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture capital (CVC) investment, acquiring an equity stake in Restore Vision Inc., a Tokyo-based startup focused on developing innovative ophthalmology technologies. This transaction marks the inaugural deal under Shionogi's CVC program, established in April 2025 to identify and cultivate next-generation growth opportunities aligned with the company's long-term strategic vision.","og_url":"https:\/\/flcube.com\/?p=63314","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-16T09:42:17+00:00","article_modified_time":"2026-04-16T09:42:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63314#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63314"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision","datePublished":"2026-04-16T09:42:17+00:00","dateModified":"2026-04-16T09:42:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63314"},"wordCount":506,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63314#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1603.webp","keywords":["Finance","Ophthalmology","Restore Vision","Shionogi","TYO: 4507"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63314#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63314","url":"https:\/\/flcube.com\/?p=63314","name":"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63314#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63314#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1603.webp","datePublished":"2026-04-16T09:42:17+00:00","dateModified":"2026-04-16T09:42:18+00:00","description":"Shionogi & Co., Ltd. (TYO: 4507) has announced the completion of its first corporate venture capital (CVC) investment, acquiring an equity stake in Restore Vision Inc., a Tokyo-based startup focused on developing innovative ophthalmology technologies. This transaction marks the inaugural deal under Shionogi's CVC program, established in April 2025 to identify and cultivate next-generation growth opportunities aligned with the company's long-term strategic vision.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63314#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63314"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63314#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1603.webp","width":1080,"height":608,"caption":"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63314#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shionogi Launches Corporate Venture Capital Initiative with Strategic Investment in Ophthalmology Startup Restore Vision"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63314"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63314\/revisions"}],"predecessor-version":[{"id":63317,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63314\/revisions\/63317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63316"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}